• Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

  • 2022/07/15
  • 再生時間： 17 分
  • ポッドキャスト

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance study

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • In this podcast, Dr. Javier Rodríguez-Carrio (1) talks to Dr. Tue Kragstrup (2) about the recent safety data on JAK inhibitors emerged after the ORAL Surveillance study. They discuss what is the current situation, the potential strategies to escape a ‘static’ situation, by managing uncertainty in the context of balancing risks, patient preferences and shared-decision process. Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236

    (1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)
    続きを読む 一部表示

あらすじ・解説

In this podcast, Dr. Javier Rodríguez-Carrio (1) talks to Dr. Tue Kragstrup (2) about the recent safety data on JAK inhibitors emerged after the ORAL Surveillance study. They discuss what is the current situation, the potential strategies to escape a ‘static’ situation, by managing uncertainty in the context of balancing risks, patient preferences and shared-decision process. Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002236

(1) Javier Rodríguez-Carrio (University of Oviedo) (@javierrcarrio); (2) Tue Wenzel Kragstrup (University of Aarhus) (@KragstrupTW)
続きを読む 一部表示

Balancing risks with JAK inhibitors in RMDs after the ORAL Surveillance studyに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。